VistaGen Therapeutics, Inc.
384 Oyster Point Boulevard
Suite 8
South San Francisco
California
94080
United States
Tel: 650-244-9990
Fax: 650-244-9979
Website: http://www.vistagen.com/
Email: rsnodgrass@vistagen.com
180 articles with VistaGen Therapeutics, Inc.
-
Vistagen to Present at Cowen 43rd Annual Health Care Conference
3/2/2023
Vistagen today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Cowen 43rd Annual Health Care Conference.
-
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
1/24/2023
Vistagen today announced the first cohort of healthy volunteers has been dosed in its U.S. Phase 1 clinical trial of PH10, the Company’s investigational pherine nasal spray in development for the treatment of major depressive disorder (MDD).
-
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
12/30/2022
Vistagen announced that the Company has taken important strategic steps to secure additional patent protection for its lead product candidate, PH94B, through the recent filing of national applications at the U.S. Patent and Trademark Office and counterpart patent authorities in major pharmaceutical markets outside the U.S. for the treatment of adjustment disorder.
-
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
11/4/2022
Vistagen today announced it will host a conference call and webcast on Thursday, November 10, 2022, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report financial results for its fiscal year 2023 second quarter ended September 30, 2022.
-
Vistagen to Present at Stifel 2022 Healthcare Conference
11/3/2022
Vistagen Therapeutics, Inc. today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Stifel 2022 Healthcare Conference taking place in New York on November 15 and 16.
-
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
10/19/2022
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company) today announced results of voting and the partial adjournment of the Company’s 2022 Annual Meeting of Stockholders (the Annual Meeting) to Friday, October 28, 2022.
-
Vistagen to Participate at Cantor Neurology & Psychiatry Conference
10/3/2022
Vistagen today announced that its Chief Executive Officer, Shawn Singh, will participate in a panel discussion regarding emerging therapies for psychiatric disorders and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference.
-
The week has seen a series of significant updates from BioVie, Regeneron, Relay Therapeutics, Oxford University, Vistagen and Palatin.
-
Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
9/9/2022
Vistagen Therapeutics, Inc. announced that Chief Executive Officer, Shawn Singh, will participate in the following upcoming investor conferences in New York.
-
Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
9/8/2022
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company) today announced the completion of an interim analysis of PALISADE-2, the Company’s second Phase 3 clinical trial assessing drug candidate PH94B as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD), which concluded that PALISADE-2 should continue as planned.
-
CRISPR Therapeutics, Clovis Oncology and VistaGen all released Q2 results this week, while GreenLight Biosciences has some extra cash to work with.
-
VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
8/11/2022
VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today reported its financial results for its first quarter of fiscal year 2023 ended June 30, 2022 and provided a corporate update.
-
VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022
8/9/2022
VistaGen Therapeutics, Inc today announced it will host a conference call and webcast on Thursday, August 11, 2022, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report financial results for its fiscal year 2023 first quarter ended June 30, 2022.
-
Prometheus completed its Phase II trial in UC, Algernon announced its Phase II trial of IPF and chronic coffee, Seelos dosed the first patient of SLS-005 for patients with ALS.
-
VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B
7/22/2022
VistaGen Therapeutics, Inc. today announced topline results from its PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder.
-
VistaGenTherapeutics announced data showing that its nasal spray candidate for anxiety, depression and other central nervous system disorders, fell short of its primary endpoint.
-
VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit
7/12/2022
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn K. Singh , will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy, MD, MBA, at the 2022 Concordia Americas Summit to discuss America’s ongoing mental health crisis.
-
VistaGen to Participate at William Blair Biotech Focus Conference 2022
7/7/2022
VistaGen to Participate at William Blair Biotech Focus Conference 2022.
-
While it was a relatively quiet week for clinical trial announcements overall, BioSpace takes a look at some of the more intriguing ones.
-
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
6/23/2022
VistaGen Therapeutics, Inc. (Nasdaq: VTGN), today reported its financial results for its fiscal year ended March 31, 2022 and provided a corporate update.